This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
SureNano Science's GlucaPharm subsidiary advances GEP-44, a novel triple agonist peptide for obesity and metabolic disease with improved tolerability and potential non-injectable delivery. #GLP1 #Biotech
2026-05-21T01:13:35.772Z